- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Opioid-Dependence Drug Bunavail (Buprenorphine/Naloxone Buccal Film) Submitted for FDA Review
Combo product absorbed through cheek or under tongue (August 1)
A New Drug Application (NDA) has been submitted to the FDA for Bunavail (buprenorphine/naloxone buccal film, BioDelivery Sciences International) for the maintenance treatment of opioid dependence. The product will be subject to a 10-month review.
Bunavail delivers buprenorphine across the buccal mucosa. It is formulated with the abuse-deterrent agent naloxone.
Buprenorphine is poorly absorbed from the gastrointestinal tract when administered orally; however, it is absorbed within the oral cavity transmucosally (across the cheek or under the tongue). The drug reduces the craving and withdrawal effects induced by the dependency-causing opioid.
According to the 2010 National Survey on Drug Use and Health, nearly 2 million Americans are dependent on prescription opioids.
Source: BioDelivery Sciences International; August 1, 2013.